Acquired resistance mechanisms to immunotherapy.
作者信息
Amaral Teresa, Garbe Claus
机构信息
Center for Dermatooncology, Department of Dermatology, Liebermeisterstrasse 25, University Hospital Tübingen, 72076 Tübingen, Germany; ; Portuguese Air Force Health Direction, Paço do Lumiar, 1649-020 Lisbon, Portugal.
Center for Dermatooncology, Department of Dermatology, Liebermeisterstrasse 25, University Hospital Tübingen, 72076 Tübingen, Germany.
出版信息
Ann Transl Med. 2016 Dec;4(24):547. doi: 10.21037/atm.2016.12.21.
Abstract
摘要
相似文献
1
Acquired resistance mechanisms to immunotherapy.
Ann Transl Med. 2016 Dec;4(24):547. doi: 10.21037/atm.2016.12.21.
2
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Oncologist. 2018 Apr;23(4):410-421. doi: 10.1634/theoncologist.2017-0354. Epub 2017 Dec 14.
3
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
4
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.
J Immunother Cancer. 2018 Dec 12;6(1):147. doi: 10.1186/s40425-018-0468-x.
5
Resistance to immunotherapy: clouds in a bright sky.
Invest New Drugs. 2017 Oct;35(5):649-654. doi: 10.1007/s10637-017-0456-x. Epub 2017 Apr 12.
6
Mechanisms of Resistance to Immune Checkpoint Antibodies.
Handb Exp Pharmacol. 2018;249:109-128. doi: 10.1007/164_2017_11.
7
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
Int Immunopharmacol. 2017 May;46:210-219. doi: 10.1016/j.intimp.2017.03.015. Epub 2017 Mar 18.
8
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor.
J Cancer. 2019 Apr 20;10(7):1764-1771. doi: 10.7150/jca.26481. eCollection 2019.
9
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
J Cancer Res Ther. 2016 Dec;12(Supplement):C131-C137. doi: 10.4103/0973-1482.200613.
10
A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance.
Adv Cancer Res. 2002;85:145-74. doi: 10.1016/s0065-230x(02)85005-9.
引用本文的文献
1
Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
Epigenomes. 2021 Jul 25;5(3):16. doi: 10.3390/epigenomes5030016.
本文引用的文献
1
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059.
2
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003.
3
Suppression of B-Raf(V600E) cancers by MAPK hyper-activation.
Oncotarget. 2016 Apr 5;7(14):18694-704. doi: 10.18632/oncotarget.7909.
4
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Eur J Cancer. 2016 Mar;55:98-110. doi: 10.1016/j.ejca.2015.12.002. Epub 2016 Jan 17.
5
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.
6
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Cell. 2015 Sep 10;162(6):1271-85. doi: 10.1016/j.cell.2015.07.061.
7
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
8
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
9
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
10
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
Zotero 插件